Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Enamelon (ENML) - Does anyone follow this? -- Ignore unavailable to you. Want to Upgrade?

To: Laptev who wrote (699)	8/5/1998 3:43:00 PM
From: Mama Bear	Respond to of 863

It looks like ENML is not going to rally today. Barb

To: Laptev who wrote (699)	8/5/1998 4:12:00 PM
From: Q.	Respond to of 863

re. <<But wouldn't it be wise to cover at book value minus a few quarters burned cash? >> that works out to about two bucks, depending on what cash burn rate you pick. What I find interesting is the aggressive schedule Fox chose to introduce his product to the market, before clinical trials allowed him to claim any distinctive advantages for the product. If instead he had done low-budget clinical trials for a few years, gotten his ADA approval to make new claims, gotten all kinds of free publicity from that, and then sought funding to do the marketing, things might have worked out better. Instead, his cash was just burning a hole in his pocket, and he couldn't wait to spend it.